Table of Contents
ISRN Endocrinology
Volume 2011, Article ID 815013, 6 pages
http://dx.doi.org/10.5402/2011/815013
Review Article

Multiple Myeloma and Diabetes

Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut-Medical Center, 3 Dag Hammarskjold Plaza, 8th floor, New York, NY 10017 , USA

Received 25 July 2011; Accepted 23 August 2011

Academic Editors: C. Gragnoli and C. M. Perks

Copyright © 2011 Zeinab A. Issa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. M. Psarakis, “Clinical challenges in caring for patients with diabetes and cancer,” Diabetes Spectrum, vol. 19, no. 3, pp. 157–162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. V. Rajkumar and R. A. Kyle, “Multiple myeloma: diagnosis and treatment,” Mayo Clinic Proceedings, vol. 80, no. 10, pp. 1371–1382, 2005. View at Google Scholar · View at Scopus
  3. S. Jagannath, “Treatment of patients with myeloma with comorbid conditions: considerations for the clinician,” Clinical Lymphoma and Myeloma, vol. 8, no. 4, supplement, pp. S149–S156, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. L. C. Richardson and L. A. Pollack, “Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer,” Nature Clinical Practice Oncology, vol. 2, no. 1, pp. 48–53, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. P. G. Richardson, P. Sonneveld, M. W. Schuster et al., “Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline,” British Journal of Haematology, vol. 144, no. 6, pp. 895–903, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. P. G. Richardson, H. Briemberg, S. Jagannath et al., “Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3113–3120, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Badros, O. Goloubeva, J. S. Dalal et al., “Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature,” Cancer, vol. 110, no. 5, pp. 1042–1049, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. E. Khan, V. Gallo, J. Linseisen et al., “Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition,” Haematologica, vol. 93, no. 6, pp. 842–850, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. B. C. H. Chiu, S. M. Gapstur, P. Greenland, R. Wang, and A. Dyer, “Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 12, pp. 2348–2354, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp, “Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. V. Rajkumar, L. Rosiñol, M. Hussein et al., “Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2171–2177, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. L. Harousseau, C Mathiot, M. Attal et al., “VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial,” Blood, vol. 110, 2007, abstract no. 450. View at Google Scholar
  13. M. Cavo, E. Zamagni, P. Tosi et al., “Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma,” Blood, vol. 106, no. 1, pp. 35–39, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. V. Rajkumar, S. Jacobus, N. S. Callander et al., “Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial,” The Lancet Oncology, vol. 11, no. 1, pp. 29–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Richardson, S. Lonial, A. Jakubowiak et al., “Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study,” Blood, vol. 112, 2008, abstract no. 92. View at Google Scholar
  16. M. Cavo, P. Tacchetti, F. Patriarca et al., “A phase III study of double autotransplantation incorporating bortezomib–thalidomide–dexamethasone (VTD) or thalidomide–dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD,” Blood, vol. 114, 2009, abstract no. 351. View at Google Scholar
  17. S. Kumar, S. Hayman, F. Buadi et al., “Phase II trial of lenalidomide (Revlimid) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma,” Blood, vol. 112, 2008, abstract no. 91. View at Google Scholar
  18. S. Kumar, I. W. Flinn, and P. N. Hari, “Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: encouraging results from the multi-center, randomized, phase 2 EVOLUTION study,” Blood, vol. 114, 2009, abstract no. 127. View at Google Scholar
  19. P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson, “New drugs for myeloma,” Oncologist, vol. 12, no. 6, pp. 664–689, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. B. Childs, M. Cypress, G. Spollett et al., Complete Nurse’s Guide to Diabetes Care, American Diabetes Association, Alexandria, Va, USA, 2005.
  21. T. Facon, J. Y. Mary, B. Pégourie et al., “Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy,” Blood, vol. 107, no. 4, pp. 1292–1298, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. J. Blade, J. F. San Miguel, A. Nagler et al., “The prolonged time to progression with pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure,” Blood, vol. 110, article 127a, 2007. View at Google Scholar
  23. S. Clement, S. S. Braithwaite, M. F. Magee et al., “Management of diabetes and hyperglycemia in hospitals,” Diabetes Care, vol. 27, no. 2, pp. 553–591, 2004. View at Publisher · View at Google Scholar
  24. J. R. Volgi and D. Baldwin, “Glucocorticoid therapy and diabetes management,” Nursing Clinics of North America, vol. 36, no. 2, pp. 333–339, 2001. View at Google Scholar · View at Scopus
  25. A. Brunello, R. Kapoor, and M. Extermann, “Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity,” American Journal of Clinical Oncology, vol. 34, no. 3, pp. 292–296, 2011. View at Publisher · View at Google Scholar · View at PubMed
  26. U. Aytac and N. H. Dang, “CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy,” Current Drug Targets, vol. 4, no. 1, pp. 11–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Hadjiyanni, K. A. Siminovitch, J. S. Danska, and D. J. Drucker, “Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells,” Diabetologia, vol. 53, no. 4, pp. 730–740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Iqbal, M. Zayed, and G. Boden, “Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes,” Diabetes Care, vol. 23, no. 8, pp. 1172–1176, 2000. View at Google Scholar · View at Scopus
  29. J. S. Wilson and J. Vallance-Owen, “Congenital deformities and insulin antagonism,” The Lancet, vol. 2, no. 7470, pp. 940–941, 1966. View at Google Scholar · View at Scopus
  30. W. D. Figg, P. Arlen, J. Gulley et al., “A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer,” Seminars in Oncology, vol. 28, no. 4, supplement 15, pp. 62–66, 2001. View at Google Scholar
  31. R. D. Pathak, K. Jayaraj, and L. Blonde, “Thalidomide-associated hyperglycemia and diabetes: case report and review of literature,” Diabetes Care, vol. 26, no. 4, pp. 1322–1323, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Plasmati, F. Pastorelli, M. Cavo et al., “Neuropathy in multiple myeloma treated with thalidomide: a prospective study,” Neurology, vol. 69, no. 6, pp. 573–581, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. I. Borrello, A. Ferguson, C. A. Huff et al., “Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma, efficacy and neurotoxicity,” Blood, 2006, ASH Annual Meeting abstracts 108, abstract no. 3528. View at Google Scholar
  34. S. Singhal, J. Mehta, R. Desikan et al., “Antitumor activity of thalidomide in refractory multiple myeloma,” New England Journal of Medicine, vol. 341, no. 21, pp. 1565–1571, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. P. K. Pal, “Clinical and electrophysiological studies in vincristine induced neuropathy,” Electromyography and Clinical Neurophysiology, vol. 39, no. 6, pp. 323–330, 1999. View at Google Scholar · View at Scopus
  36. A. A. Argyriou, G. Iconomou, and H. P. Kalofonos, “Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature,” Blood, vol. 112, no. 5, pp. 1593–1599, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. P. G. Richardson, P. Sonneveld, M. W. Schuster et al., “Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline,” British Journal of Haematology, vol. 144, no. 6, pp. 895–903, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. A. Palumbo, F. Davies, M. Kropff et al., “Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma,” Annals of Hematology, vol. 89, no. 8, pp. 803–811, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. F. Boya, B. Laruant, M. Pajouhi, J. Lofti, M. M. Noraii, and F. Bandarian, “Peripheral neuropathy in diabetic patients and its contributing factors,” Iranian Journal of Diabetes and Lipid Disorders, vol. 3, no. 1, pp. 41–46, 2003. View at Google Scholar
  40. L. Almadrones, D. B. McGuire, J. R. Walczak, C. M. Florio, and C. Tian, “Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study,” Oncology Nursing Forum, vol. 31, no. 3, pp. 615–623, 2004. View at Google Scholar · View at Scopus
  41. J. Bladé, P. Fernández-Llama, F. Bosch et al., “Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution,” Archives of Internal Medicine, vol. 158, no. 17, pp. 1889–1893, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. National Kidney Foundation, “Kidney Disease Outcomes Quality Initiative (NKF-KDOQI): clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease,” American Journal of Kidney Diseases, vol. 49, pp. S1–S179, 2007. View at Google Scholar
  43. S. M. Korbet and M. M. Schwartz, “Multiple myeloma,” Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2533–2545, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. M. Santostefano, F. Zanchelli, A. Zaccaria, G. Poletti, and M. Fusaroli, “The ultrastructural basis of renal pathology in monoclonal gammopathies,” Journal of Nephrology, vol. 18, no. 6, pp. 659–675, 2005. View at Google Scholar · View at Scopus
  45. L. M. Knudsen, E. Hippe, M. Hjorth, E. Holmberg, and J. Westin, “Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients,” European Journal of Haematology, vol. 53, no. 4, pp. 207–212, 1994. View at Google Scholar
  46. “REVLIMID® (lenalidomide) Product Information,,” Celgene Corporation Summit, NJ 07901, USA, January 2009.
  47. P. Gæde, H. Lund-Andersen, H. H. Parving, and O. Pedersen, “Effect of a multifactorial intervention on mortality in type 2 diabetes,” New England Journal of Medicine, vol. 358, no. 6, pp. 580–591, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. A. E. Omoti and C. E. Omoti, “Ophthalmic manifestations of multiple myeloma,” West African Journal of Medicine, vol. 26, no. 4, pp. 265–268, 2007. View at Google Scholar · View at Scopus
  49. The Emerging Risk Factors Collaboration, “Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies,” The Lancet, vol. 375, no. 9733, pp. 2215–2222, 2010. View at Publisher · View at Google Scholar
  50. X. S. Hu, C. Q. Du, L. Yang, X. Y. Yao, and S. J. Hu, “Proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells: involvement of nitric oxide synthase inhibition,” International Journal of Molecular Medicine, vol. 25, no. 3, pp. 385–392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Nakayama, H. Yasue, M. Yoshimura et al., “T-786 → C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm,” Circulation, vol. 99, no. 22, pp. 2864–2870, 1999. View at Google Scholar · View at Scopus
  52. R. Govers, P. De Bree, and T. J. Rabelink, “Involvement of the proteasome in activation of endothelial nitric oxide synthase,” Life Sciences, vol. 73, no. 17, pp. 2225–2236, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Belloni, L. Veschini, C. Foglieni et al., “Bortezomib induces autophagic death in proliferating human endothelial cells,” Experimental Cell Research, vol. 316, no. 6, pp. 1010–1018, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. S. Meiners, M. Laule, W. Rother et al., “Ubiquitin-proteasome pathway as a new target for the prevention of restenosis,” Circulation, vol. 105, no. 4, pp. 483–489, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. W. Martinet and M. M. Kockx, “Apoptosis in atheroclerosis: implications for plaque destabilization,” Verhandelingen—Koninklijke Academie voor Geneeskunde van Belgie, vol. 66, no. 1, pp. 61–79, 2004. View at Google Scholar · View at Scopus
  56. M. M. Kavurma, R. Bhindi, H. C. Lowe, C. Chesterman, and L. M. Khachigian, “Vessel wall apoptosis and atherosclerotic plaque instability,” Journal of Thrombosis and Haemostasis, vol. 3, no. 3, pp. 465–472, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. D. Versari, J. Herrmann, M. Gössl et al., “Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 9, pp. 2132–2139, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. D. Sedaghat, R. M. Zakir, J. Choe, M. Klapholz, and M. Saric, “Cardiac amyloidosis in a patient with multiple myeloma: a case report and review of literature,” Journal of Clinical Ultrasound, vol. 37, no. 3, pp. 179–184, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. H. Pérez-Díaz, A. Serrano-Pozo, and J. R. González-Marcos, “Multiple myeloma as a treatable cause of stroke: clinical case and review of the literature,” Neurologia, vol. 22, no. 1, pp. 54–57, 2007. View at Google Scholar · View at Scopus
  60. Z. T. Bloomgarden, “Diabetes and cancer,” Diabetes Care, vol. 24, pp. 780–781, 2001. View at Google Scholar